Early gene therapy trial aims to slow vision loss in rare eye disease
NCT ID NCT06196827
Summary
This is an early-stage study testing a one-time gene therapy called LX101 for people with a rare inherited eye disease that causes progressive vision loss. The goal is to see if the treatment is safe and if it can improve or stabilize vision. Nine participants, aged 6 and older with a specific genetic mutation, will have the therapy injected into one eye.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INHERITED RETINAL DYSTROPHY ASSOCIATED WITH RPE65 MUTATIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tongren Hospital, Capital Medical University
Beijing, China
-
Shanghai General Hospital
Shanghai, China
Conditions
Explore the condition pages connected to this study.